Check out this great video
It is our pleasure to invite you to our 1st International transplant Symposium to be held on:
Saturday 19th and Sunday 20th Oct 2019
(Click here to find out more about Kent in England)
Please note: Places are limited to 180 Only
International attendees, check if you require visa to enter the UK - Click here
To find accomodation in Kent - Click here
For more info on getting to Kent, England - Click Here
The main focus of the Symposium will be rehabilitation in:
A total of 1 million stem cell transplants (bone marrow, peripheral blood or umbilical cord blood) have been performed worldwide, with more than 40,000 transplants reported in Europe alone each year.
Although HCT has resulted in improved mortality rate, however, a myriad of treatment related complications has been reported thus resulting in poor quality of life in patients. Chronic graft versus host disease (cGVHD) is one such post HCT complication that can affect up to 80% of the transplant recipients.
cGVHD can manifest in different patients differently in variation, spread, severity, and can include disorders such as scleroderma, fasciitis, polymyositis, myopathies, Sjögren’s syndrome, neurological sequelae, primary biliary cirrhosis, vaginal GVHD, wasting syndrome, genital GVHD, bronchiolitis obliterans, immune cytopenias, and chronic immunodeficiency.
Despite a six-decade history of allogenic HCT, the pharmacological interventions used for the prevention of GVHD have limited utility.
Over 100,000 solid organ transplants are performed worldwide each year and this has a significant impact on physical function and quality of life.
As the improved mortality rate among the solid organ transplant recipient is growing and patients are living longer, there are growing concerns about the associated comorbidities.
Post-transplant between 40–60% of the patients suffer from reduced maximal exercise capacity and other problems such as cardiopulmonary problems and musculoskeletal pathologies including arthralgia, osteoarthritis, peripheral neuropathy, and myalgia. These patients generally also suffer from decreased bone density especially in first year of life which can result in an increased incidence of skeletal fractures.
The rate of complications reportedly are increased with time elapsed from transplantation.
The current symposium highlights some of the challenges faced by the rehabilitation specialists working with Hematopoietic Cell and Solid Organ Transplant and will also provide evidence based management strategies to achieve optimal gains for the patients.
This symposium is being organised by the Rehabilitation Association for Hematopoietic Cell Transplant , a part of QUALITYFORLIFE CIC (community interest company - uses their profits and assets for the public good), registered with the company house in England, UK. (Formerly known as Transplant Rehab Ltd)
We are like minded professionals from diverse medical background with keen interest in finding evidence based innovative ideas in managing various musculoskeletal manifestations in HCT and cGVHD. We have in our multidisciplinary team, volunteer healthcare professionals from various parts of the world including Austria, Australia, Belgium, Canada, Croatia, Egypt, France, Germany, India, Italy, Nigeria, Oman, Poland, Qatar, Russia, Saudi Arabia, Swiss, USA, UK etc. & more countries joining each week.
Our team consists of HCT Consultants, Physical Therapists, Occupational Therapists, Specialist Nurses and Speech Therapists.
Copyright © 2019 QUALITYFORLIFE CIC is a (Not for Profit) company registered in England with company number 12037798
- All Rights Reserved.